Has David Lam, MD received payments from drug or device companies?

Yes. Drug and device makers reported $893 in general payments to David Lam, MD across 14 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean David Lam, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about David Lam, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

David Lam, MD

Endocrinology, Diabetes & Metabolism · New York, NYNPI 1760662019

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 14 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 5 manufacturers reported payments, led by Abbott at 56.1% of the total. That places this record below the midpoint for endocrinology, diabetes & metabolism clinicians in NY, where the typical reported total is $1,058.

$893in general payments, 2019–2025

Across 14 payments — averaging $63.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Abbott$501
Dexcom, Inc.$193
Tandem Diabetes Care, Inc.$150
Novartis$29
Amgen$20

$384,987in research payments, 2019–2025

Across 6 payments — averaging $64,164 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Renalytix AI, Inc.$364K
Sanofi US Services Inc.$20K
Lexicon Pharmaceuticals, Inc.$2K

What the payments were for

Food & beverage$893100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Abbott	9	$501
Dexcom, Inc.	2	$193
Tandem Diabetes Care, Inc.	1	$150
Novartis	1	$29
Amgen	1	$20

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$893 in reported general payments places this provider in the 45th percentile of 804 endocrinology, diabetes & metabolism providers in New York.

See all endocrinology, diabetes & metabolism providers in New York →

Medicare billing

Part B allowed, 2024

$48,469

Medicare patients

164

Services billed

623

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
OzempicSemaglutide	137	$245,971
MounjaroTirzepatide	115	$169,634
JardianceEmpagliflozin	101	$142,229
TrulicityDulaglutide	53	$102,241
FarxigaDapagliflozin Propanediol	50	$61,780
JanuviaSitagliptin Phosphate	44	$45,154
RybelsusSemaglutide	14	$20,154
Novolog FlexpenInsulin Aspart	53	$14,873
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7	14	$13,147
Tresiba Flextouch U-100Insulin Degludec	18	$12,785
JanumetSitagliptin Phos/Metformin Hcl	12	$12,017
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog	37	$11,215
NovologInsulin Aspart	17	$9,197
HumalogInsulin Lispro	25	$8,093
Lantus SolostarInsulin Glargine,hum.Rec.Anlog	66	$7,914

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in New York

John BilezikianNew York$809K
Anastasios ManessisNew York$656K
Jason BakerNew York$427K
Brian LevyNew York$417K
Stuart WeissNew York$275K
Priya JaisinghaniNew York$239K
Henry GinsbergNew York$161K
Recaredo BerbanoNew York$146K
Beverly TchangNew York$120K
Shira EytanNew York$96K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →